| Dr Marcus R Hennon, DO | |
|
100 Hospital Dr, Lebanon, MO 65536-9210 | |
| (417) 533-6100 | |
| Not Available |
| Full Name | Dr Marcus R Hennon |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine - Emergency Medical Services |
| Location | 100 Hospital Dr, Lebanon, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568811321 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 125069113 (Illinois) | Secondary |
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 2018022565 (Missouri) | Primary |
| Entity Name | Mercy Hospital Cassville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285676932 PECOS PAC ID: 8820999139 Enrollment ID: O20040120000164 |
News Archive
Nearly one in five consumers say their concern over the H1N1 flu will cause them to avoid shopping on traditionally busy retail days during the 2009 holiday season, according to a recent Morpace Omnibus Study.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Hepatocellular carcinoma is a long medical name for the most common form of liver cancer, a malignancy whose incidence has nearly doubled over the past decade, making it the fastest growing type of cancer in the U.S., and the third-leading cause of cancer-related death worldwide.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 2 days ago
| Entity Name | Ozarks Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831115641 PECOS PAC ID: 3870491863 Enrollment ID: O20040209001035 |
News Archive
Nearly one in five consumers say their concern over the H1N1 flu will cause them to avoid shopping on traditionally busy retail days during the 2009 holiday season, according to a recent Morpace Omnibus Study.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Hepatocellular carcinoma is a long medical name for the most common form of liver cancer, a malignancy whose incidence has nearly doubled over the past decade, making it the fastest growing type of cancer in the U.S., and the third-leading cause of cancer-related death worldwide.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 2 days ago
| Entity Name | Mercy Hospital Aurora |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467543090 PECOS PAC ID: 9436063211 Enrollment ID: O20040727000335 |
News Archive
Nearly one in five consumers say their concern over the H1N1 flu will cause them to avoid shopping on traditionally busy retail days during the 2009 holiday season, according to a recent Morpace Omnibus Study.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Hepatocellular carcinoma is a long medical name for the most common form of liver cancer, a malignancy whose incidence has nearly doubled over the past decade, making it the fastest growing type of cancer in the U.S., and the third-leading cause of cancer-related death worldwide.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 2 days ago
| Entity Name | Mercy Hospital Lebanon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447284898 PECOS PAC ID: 7214829019 Enrollment ID: O20040907000806 |
News Archive
Nearly one in five consumers say their concern over the H1N1 flu will cause them to avoid shopping on traditionally busy retail days during the 2009 holiday season, according to a recent Morpace Omnibus Study.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Hepatocellular carcinoma is a long medical name for the most common form of liver cancer, a malignancy whose incidence has nearly doubled over the past decade, making it the fastest growing type of cancer in the U.S., and the third-leading cause of cancer-related death worldwide.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 2 days ago
| Entity Name | Mercy Hospital Aurora |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1467543090 PECOS PAC ID: 9436063211 Enrollment ID: O20061104000261 |
News Archive
Nearly one in five consumers say their concern over the H1N1 flu will cause them to avoid shopping on traditionally busy retail days during the 2009 holiday season, according to a recent Morpace Omnibus Study.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Hepatocellular carcinoma is a long medical name for the most common form of liver cancer, a malignancy whose incidence has nearly doubled over the past decade, making it the fastest growing type of cancer in the U.S., and the third-leading cause of cancer-related death worldwide.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 2 days ago
| Entity Name | Mercy Hospital Cassville |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1285676932 PECOS PAC ID: 8820999139 Enrollment ID: O20100118000033 |
News Archive
Nearly one in five consumers say their concern over the H1N1 flu will cause them to avoid shopping on traditionally busy retail days during the 2009 holiday season, according to a recent Morpace Omnibus Study.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Hepatocellular carcinoma is a long medical name for the most common form of liver cancer, a malignancy whose incidence has nearly doubled over the past decade, making it the fastest growing type of cancer in the U.S., and the third-leading cause of cancer-related death worldwide.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 2 days ago
| Entity Name | Mercy Hospital Carthage |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1003201955 PECOS PAC ID: 8426225251 Enrollment ID: O20141203001963 |
News Archive
Nearly one in five consumers say their concern over the H1N1 flu will cause them to avoid shopping on traditionally busy retail days during the 2009 holiday season, according to a recent Morpace Omnibus Study.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Hepatocellular carcinoma is a long medical name for the most common form of liver cancer, a malignancy whose incidence has nearly doubled over the past decade, making it the fastest growing type of cancer in the U.S., and the third-leading cause of cancer-related death worldwide.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marcus R Hennon, DO 2418 W Crestwood # Mo65721, Ozark, MO 65721-5997 Ph: (417) 551-2203 | Dr Marcus R Hennon, DO 100 Hospital Dr, Lebanon, MO 65536-9210 Ph: (417) 533-6100 |
News Archive
Nearly one in five consumers say their concern over the H1N1 flu will cause them to avoid shopping on traditionally busy retail days during the 2009 holiday season, according to a recent Morpace Omnibus Study.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Hepatocellular carcinoma is a long medical name for the most common form of liver cancer, a malignancy whose incidence has nearly doubled over the past decade, making it the fastest growing type of cancer in the U.S., and the third-leading cause of cancer-related death worldwide.
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
› Verified 2 days ago
Evan E. Fusco, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 100 Hospital Dr, Lebanon, MO 65536 Phone: 417-533-6100 Fax: 417-533-6021 | |
Dr. Danelle M Richards, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Hospital Dr, Lebanon, MO 65536 Phone: 417-533-6100 | |
Dr. Jeffrey Bond, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 100 Hospital Dr, Lebanon, MO 65536 Phone: 417-533-6100 | |
Dr. Anthony Jacob Pappas, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Hospital Dr, Lebanon, MO 65536 Phone: 417-533-6100 | |
Dr. Gregory R Goodwin, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 100 Hospital Dr, Lebanon, MO 65536 Phone: 417-533-6100 Fax: 417-533-6173 | |
Donald Edward Hockman Ii, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Hospital Dr, Lebanon, MO 65536 Phone: 417-533-6100 | |
Dr. Erik Lee Snyder, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Hospital Dr, Lebanon, MO 65536 Phone: 417-533-6100 |